News

The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immune pathways. While a “cytokine storm” involving IL-6 and other […]

Read More →

Το Βήμα: Νέα φαρμακευτική ελπίδα ενάντια στον SARS-CoV-2

Στη μάχη εναντίον του νέου κορωνοϊού έχει ριχθεί ελληνική φαρμακευτική εταιρεία που αναπτύσσει καινοτόμα φάρμακα για την αντιμετώπιση φλεγμονωδών παθήσεων μέσω της στόχευσης μορίων του συμπληρώματος, ενός κομβικού μηχανισμού φυσικής ανοσίας του οργανισμού, ξεκινώντας τη χορήγηση του πρωτότυπου πειραματικού της φαρμάκου, ΑΜΥ-101, σε ασθενείς με COVID-19 στην Ιταλία. Μάλιστα σε […]

Read More →

Καινοτόμο φάρμακο για τη θεραπεία της περιοδοντίτιδας της Ελληνικής Εταιρείας Amyndas Pharmaceuticals

Tην πρώτη πειραματική κλινική μελέτη για το καινοτόμο φάρμακο AMY-101, σε ενήλικες με περιοδοντική νόσο ανακοίνωσε η ελληνική φαρμακευτική start-up, Amyndas Pharmaceuticals, που πρωτοπορεί διεθνώς στον τομέα των αντιφλεγμονωδών θεραπειών. Πρόκειται για την κλινική δοκιμή του νέου φαρμάκου ΑMY-101, η οποία θα διεξαχθεί στις ΗΠΑ, και στόχος της είναι να […]

Read More →

Amyndas Pharmaceuticals Initiates Phase 2a study of AMY-101 in adults with Periodontal inflammation and Gingivitis

Amyndas Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of novel complement therapeutics, announced today the launch of its Phase 2a clinical study, evaluating AMY-101 in adults with periodontal inflammation and gingivitis. AMY-101 is a novel synthetic cyclic peptide designed to inhibit the complement cascade centrally at the level […]

Read More →

Amyndas Pharmaceuticals Initiates Phase 2a study of AMY-101 in adults with Periodontal inflammation and Gingivitis

Amyndas Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of novel complement therapeutics, announced today the launch of its Phase 2a clinical study, evaluating AMY-101 in adults with periodontal inflammation and gingivitis. AMY-101 is a novel synthetic cyclic peptide designed to inhibit the complement cascade centrally at the level […]

Read More →

High Point Clinical Trials Center and Amyndas Pharmaceuticals Announce the Completion of the Complement C3 Inhibitor AMY-101 First in Human Study

High Point Clinical Trial Center (HPCTC) and Amyndas Pharmaceuticals jointly announce the completion of the AMY-101 First in Human (FIH) study, which assessed safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) after a Single Ascending Dose (SAD) and Multiple Doses (MD) of AMY-101 administered systemically (via subcutaneous or intravenous routes) in […]

Read More →

High Point Clinical Trials Center and Amyndas Pharmaceuticals Announce the Completion of the Complement C3 Inhibitor AMY-101 First in Human Study

High Point Clinical Trial Center (HPCTC) and Amyndas Pharmaceuticals jointly announce the completion of the AMY-101 First in Human (FIH) study, which assessed safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) after a Single Ascending Dose (SAD) and Multiple Doses (MD) of AMY-101 administered systemically (via subcutaneous or intravenous routes) in […]

Read More →

Amyndas Pharmaceuticals Announces Positive Results from a Phase I Trial of its new complement C3 inhibitor AMY-101

13th December 2017 / Sciad Newswire / Amyndas Pharmaceuticals, which is committed to developing innovative therapeutics for complement-mediated conditions, today announced positive preliminary results from a Phase 1 clinical trial of its C3-targeted complement inhibitor, AMY-101. The phase I which has just been completed, was a prospective, single-center, open-label, First-In-Human (FIH) clinical […]

Read More →

Press Release: Amyndas Pharmaceuticals Announces Positive Results from a Phase I Trial of its complement C3 inhibitor AMY-101

Amyndas Pharmaceuticals, which is committed to developing innovative therapeutics for complement-mediated conditions, today announced positive preliminary results from a Phase 1 clinical trial of its C3-targeted complement inhibitor, AMY-101. The phase I which has just been completed, was a prospective, single-center, open-label, First-In-Human (FIH) clinical study, designed to assess the […]

Read More →